Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study ...

Company to present 40-week topline results from the Phase 2 study of migaldendranib (MGB), a first-in-class subcutaneous nanomedicine, being developed for the treatment of DME and nAMD FDA alignment ...

Discover Harrow Inc.'s growth strategy, bullish long-term prospects, and Q3 earnings outlook in ophthalmology. Click for more on HROW stock ahead of earnings.

In this video from the American Academy of Ophthalmology meeting, Diana V. Do, MD, said aflibercept 8 mg showed vision improvement and a reduction in retinal thickness.

Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for ...

A recent study published in the Journal of Cataract & Refractive Surgery found that Yttrium Aluminum Garnet (YAG) laser ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. China Medical System Holdings ( (HK:0867) ...